FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS Share Price

Certificat

DE000MB2SNQ9

Market Closed - Börse Stuttgart 20:58:04 21/05/2024 BST
0.4 EUR -20.00% Intraday chart for FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS
Current month-54.55%
1 month-51.81%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
21/05/24 0.4 -20.00%
20/05/24 0.5 +28.21%
17/05/24 0.39 -2.50%
16/05/24 0.4 -31.03%
15/05/24 0.58 +11.54%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 08:58 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MB2SNQ
ISINDE000MB2SNQ9
Date issued 25/01/2023
Strike 32.27 $
Maturity Unlimited
Parity 11.82 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 12.81
Lowest since issue 0.37
Spread 0.01
Spread %2.44%

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
37.37 USD
Average target price
57.95 USD
Spread / Average Target
+55.07%
Consensus